Biopharmaceutical_third-party_logistics_Market.JPG

Biopharmaceutical Third-Party Logistics Market Size, Share & Trends Analysis Report by Supply Chain (Cold Chain, Non-cold Chain), By Service Type (Transportation, Warehousing & Storage), Region And Segment Forecasts, 2025-2034

Report Id: 1935 Pages: 180 Published: 11 July 2025 Format: PDF / PPT / Excel / Power BI
Share With : linkedin twitter facebook

Global Biopharmaceutical Third-Party Logistics Market Size is valued at USD 141.4 Bn in 2024 and is predicted to reach USD 264.8 Bn by the year 2034 at an 6.6% CAGR during the forecast period for 2025-2034.

Third-party logistics (3PL) for the biopharmaceutical industry describes the logistical support provided to pharmaceutical firms by unaffiliated businesses. For instance, it involves filling orders, keeping track of the inventory of the goods using a warehouse management system, and receiving medications consisting of tiny molecules into the warehouse. For instance, by reducing unnecessary overhead costs, ensuring continuous product supply, optimizing transportation, and increasing the organization's general efficiency, 3PL helps pharmaceutical and medical institutions maintain logistics for the distribution of medical medicines.

Biopharmaceutical Third-Party Logistics Market

The pharmaceutical industry's tremendous rise is largely to blame for the market's optimistic outlook. The market is also increasing due to the rising trend among medical businesses to outsource logistics to increase their distribution network. Some of the major drivers propelling the market include the rising trend of outsourcing logistics, the concentration of pharmaceutical manufacturers on their distribution network due to its strong sales statistics, and an increase in the number of biosimilar launches. The COVID-19 pandemic had a substantial effect on market expansion.

Additionally, Celcius Logistics debuted its Hyper-Local temperature-controlled delivery services for food and pharmaceutical orders in November 2022. Over the past few years, the demand for outsourcing transportation services has seen a noticeable increase. Giant pharmaceutical corporations' overhead has decreased due to outsourcing the transportation services for transporting pharmaceutical medications. To further encourage lean management and using six sigma in their business operations, the major biopharma corporations are either consenting to or outsourcing to 3PL service providers.  

Competitive Landscape:

Some of the major key players in the Biopharmaceutical third-party logistics market are:

  • DHL International GmbH
  • SF Express
  • United Parcel Service of America Inc.
  • AmerisourceBergen Corp.
  • DB Schenker
  • Kuehne and Nagel
  • Kerry Logistics Network Ltd.
  • Agility 

Market Segmentation:

The Biopharmaceutical third-party logistics market is segmented on the basis of supply chain and service type.Supply chain segments includes Cold Chain and Non-Cold Chain. The market is segmented by service type into Transportation, Warehousing & Storage, and Others.

Based On Service Type, The Warehousing And Storage Segment Is Accounted As A Major Contributor In The Biopharmaceutical Third-Party Logistics Market

In 2022, the warehousing and storage industry dominated the market, generating more than 43.30% of the total revenue. The increasing demand for 3PL services from the pharmaceutical and healthcare sectors is to blame for this. The life sciences industry is using 3PL services to lower overhead expenditures and operating costs.

The Cold Chain Segment Witnessed Growth At A Rapid Rate

Over the forecast period, the cold chain segment is anticipated to post the quickest CAGR. This is primarily due to the increase in demand for biologics, a novel class of pharmaceuticals that has shown rapid growth in recent years. Aside from biologics, the market has witnessed the emergence of various types of precision medicine inventions, such as biomarker testing, cellular therapies, specific vaccines, blood products, and regenerative medicine in the form of stem cells. These drugs require both temperature- and time-controlled distribution.

The North America Biopharmaceutical Third-Party Logistics Market Holds A Significant Revenue Share In The Region

With a market share of about 39.1% and 119.8 billion dollars in revenue, North America emerged as the largest market for worldwide third-party logistics for biopharmaceuticals. This industry's fundamental engine of growth is the increased import and export of pharmaceutical chemicals, drugs, biologics, vaccines, and other related goods.

In addition to having high medical expenses, this area has the highest adoption of cutting-edge technologies overall. Because of this, North American pharmaceutical companies rely more and more on 3PL service providers to enhance storage and shipping, fueling the region's overall growth. However, the Asia-Pacific market remains second due to increased investment in R&D and an increase in the number of diagnoses of rare illnesses in the region; the Asia-Pacific market is anticipated to grow at the quickest CAGR. It is anticipated that this element will improve pharmaceutical product sales as well as their import and export.

Biopharmaceutical Third-Party Logistics Market Report Scope:

Report Attribute

Specifications

Market Size Value In 2024

USD 141.4 Bn

Revenue Forecast In 2034

USD 264.8 Bn

Growth Rate CAGR

CAGR of 6.6% from 2025 to 2034

Quantitative Units

Representation of revenue in US$ Million, and CAGR from 2025 to 2034

Historic Year

2021 to 2024

Forecast Year

2025-2034

Report Coverage

The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends

Segments Covered

Supply Chain And Service Type

Regional Scope

North America; Europe; Asia Pacific; Latin America; Middle East & Africa

Country Scope

U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; The UK; France; Italy; Spain; China; Japan; India; South Korea; Southeast Asia; South Korea; Southeast Asia

Competitive Landscape

DHL International GmbH, SF Express, United Parcel Service of America Inc., AmerisourceBergen Corp., DB Schenker, Kuehne and Nagel, Kerry Logistics Network Ltd., and Agility.

Customization Scope

Free customization report with the procurement of the report, Modifications to the regional and segment scope. Particular Geographic competitive landscape.

Pricing and Available Payment Methods

Explore pricing alternatives that are customized to your particular study requirements.

Need Customization
Need specific information/chapter from the report of the custom data table, graph or complete report? Tell us more.

Deprecated: stripslashes(): Passing null to parameter #1 ($string) of type string is deprecated in /home/z8nbkwptb7pj/public_html/report-details.php on line 233

Segmentation of Biopharmaceutical third-party logistics Market-

By Supply Chain-

  • Cold Chain
  • Non-Cold Chain

Biopharmaceutical third-party logistics Market

By Service Type-

  • Transportation
    • Air Freight
    • Sea Freight
    • Overland
  • Warehousing & Storage
  • Others Services

By Region-

North America-

  • The US
  • Canada

Europe-

  • Germany
  • The UK
  • France
  • Italy
  • Spain
  • Rest of Europe

Asia-Pacific-

  • China
  • Japan
  • India
  • South Korea
  • South East Asia
  • Rest of Asia Pacific

Latin America-

  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America

 Middle East & Africa-

  • GCC Countries
  • South Africa
  • Rest of Middle East and Africa

 InsightAce Analytic follows a standard and comprehensive market research methodology focused on offering the most accurate and precise market insights. The methods followed for all our market research studies include three significant steps – primary research, secondary research, and data modeling and analysis - to derive the current market size and forecast it over the forecast period. In this study, these three steps were used iteratively to generate valid data points (minimum deviation), which were cross-validated through multiple approaches mentioned below in the data modeling section.

Through secondary research methods, information on the market under study, its peer, and the parent market was collected. This information was then entered into data models. The resulted data points and insights were then validated by primary participants.

Based on additional insights from these primary participants, more directional efforts were put into doing secondary research and optimize data models. This process was repeated till all data models used in the study produced similar results (with minimum deviation). This way, this iterative process was able to generate the most accurate market numbers and qualitative insights.

Secondary research

The secondary research sources that are typically mentioned to include, but are not limited to:

  • Company websites, financial reports, annual reports, investor presentations, broker reports, and SEC filings.
  • External and internal proprietary databases, regulatory databases, and relevant patent analysis
  • Statistical databases, National government documents, and market reports
  • Press releases, news articles, and webcasts specific to the companies operating in the market

The paid sources for secondary research like Factiva, OneSource, Hoovers, and Statista

Primary Research:

Primary research involves telephonic interviews, e-mail interactions, as well as face-to-face interviews for each market, category, segment, and subsegment across geographies

The contributors who typically take part in such a course include, but are not limited to: 

  • Industry participants: CEOs, CBO, CMO, VPs, marketing/ type managers, corporate strategy managers, and national sales managers, technical personnel, purchasing managers, resellers, and distributors.
  • Outside experts: Valuation experts, Investment bankers, research analysts specializing in specific markets
  • Key opinion leaders (KOLs) specializing in unique areas corresponding to various industry verticals
  • End-users: Vary mainly depending upon the market

Data Modeling and Analysis:

In the iterative process (mentioned above), data models received inputs from primary as well as secondary sources. But analysts working on these models were the key. They used their extensive knowledge and experience about industry and topic to make changes and fine-tuning these models as per the product/service under study.

The standard data models used while studying this market were the top-down and bottom-up approaches and the company shares analysis model. However, other methods were also used along with these – which were specific to the industry and product/service under study.

To know more about the research methodology used for this study, kindly contact us/click here.

Name field cannot be blank!
Email field cannot be blank!(Use email format)
Email field cannot be blank!(Use email format)
Company field cannot be blank!
Contact No field cannot be blank!
Message field cannot be blank!
7107
Security Code field cannot be blank!
Frequently Asked Questions

Inhalable Biologics Market is valued at USD 3.8 Billion in 2024 and is predicted to reach USD 17.2 Billion by the year 2034

Inhalable Biologics Market is expected to grow at a 19.4% CAGR during the forecast period for 2025-2034.

Kamada Pharmaceuticals, MannKind Corporation, Ab Initio Pharma, Ocugen, Inc., CanSino Biologics, and AstraZeneca.

Type, Application, Dosage Form, And Distribution Channel are the key segments of the Inhalable Biologics Market.

North America region is leading the Inhalable Biologics Market.